Product Images Crysvita

This appears to be a graph showing a comparison between a placebo and a drug named CRYSVITA on serum phosphorus levels during a double-blinded period followed by an open-label period. There are two groups represented by N=66 and N=68. The Y-axis shows serum phosphorus levels ranging from 1.5 to 5.0+ and the X-axis shows the different treatment regimens. However, some of the characters in the text are not readable.*

This text appears to be a drug label for a medication called CRYSVITA, produced by Kyowa Kifn Inc, with an NDC code of 6979410201. It is an injection with a maximum volume per injection site of 15L and needs to be refrigerated and protected from light. It contains no preservatives and only comes in a single-dose vial. The label also provides other details for use and storage.*

This is a description of a pharmaceutical product called CRYSVITA which is administered via injection subcutaneously. The product comes in a single-dose vial and contains 30mg of burosumab-twza. There are no preservatives in the product. It must be refrigerated and stored in the original carton to protect it from light. The maximum volume of CRYSVITA per injection site is 1 mL. The package insert should be referred to for dosage and administration instructions. This a product of Kyowa Kirin, Inc., and is manufactured by Ultragenyx Pharmaceutical Inc. The address of the manufacturer is Novato, CA 94349.*

This appears to be a description of a medication called "souton" (although the correct name is not clear from the text). It contains 20mg of a substance called burosumab, as well as other ingredients including lohisticine and cpenarrerine. The medication is supplied in a vial marked with the NDC code 6979420301, and is distributed by Utgenyx. It must be refrigerated and stored at a temperature between 2°C and 8°C. The medication is intended for subcutaneous use only and is provided in a single-dose vial which should not be frozen or shaken. Remaining medication should be discarded.*